IL1F10 and cancer: When combining IL-38 blockade with doxorubicin treatment in a late-stage cancer therapeutic setting starting at a tumor size of 1 cm (figure 3C), we observed that combination of IL-38 blockade with doxorubicin limited tumor progression, whereas chemotherapy alone did not (figure 3D,E).